S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
Table 1
Demographic and clinical data of study participants.
Parameter
Baseline
8 weeks (LOCF)
Reduction from baseline (%)
Statistics
Gender
Male, n (%)
11 (43.2%)
—
—
—
Female, n (%)
14 (56.8%)
—
—
—
Age, years: mean (SD)
32.0 (5.1)
—
—
—
Age at onset, years: mean (SD)
25.0 (5.1)
—
—
—
Duration of illness, years: mean (SD)
8.0 (2.8)
—
—
—
Experience of hospitalizations: yes, n (%)
9 (36%)
—
—
—
History of suicidal attempt: yes, n (%)
6 (24%)
—
—
—
HAM-D total score: mean (SD)
28.0 (2.9)
10.9 (5.5)
61.1
F = 131.3, df = 8, P < 0.001
SHAPS total score: mean (SD)
6.9 (2.2)
3.6 (2.5)
52
t = 5.0, df = 48, P < 0.001
SDS total score: mean (SD)
16.6 (3.2)
6.7 (5.2)
61.6
t = 8.2, df = 48, P < 0.001
HAM-D: Hamilton Rating Scale for Depression; SHAPS: Snaith-Hamilton Pleasure Scale; SDS: Sheehan Disability Scale (SDS).
